Domaine de Maîtrise :
Essais Cliniques

Domaine d’intérêt :
Essais Cliniques, Recherche Clinique ​

Les publications :
1. Quality of life of early stage colorectal cancer patients in Morocco. H.MRABTI, M.AMZIREN; I.EL GHISSASSI; Y.BENSOUDA; N.BERRADA; H.ABAHSSAIN; S.EL FAKIR; C.NEJJARI; A.BENIDER; N.MELLAS; O.EL MESBAHI; M.BENNANI; R.BEKKALI; A.ZIDOUH; H.ERRIHANI. BMC Gastroenterology, Accepted for publication on 9-06-2016, Reference: BMGE-D-15-00036R2

2. Metastatic colorectal cancer: new therapeutic agents and new strategies. H.MRABTI, H. ABAHSSAIN, I.ELGHISSASSI, S.BOUTAYEB, N.BERRADA, K.EL HASSANI, H.ERRIHANI. Hegel, Janvier 2015, Volume 5, supplement N°1

3. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer.H. Mrabti, C. De la Fouchardiere, F. Desseigne, S. Dussart, S. Negrier, H. Errihani. J Cancer Res Ther. 2009 Oct-Dec;5(4):272-6. 4. Intestinal non-Hodgkin lymphoma: "Immunoproliferative small intestinal disease.Mrabti H, Raiss G, Raissouni S, Tazi EM, Inghaouen H, El Ghissassi I, Errihani H. Presse Med. 2011; 40: 995–1000.

5. Chemotherapy in nasopharyngeal carcinoma Ann Otolaryngol Chir Cervicofac.M'Rabti H, Sbiti Y, Afqir S, Boutayeb S, Errihani H. 2006 Apr;123(2):59-64.

6. Metastatic Desmoplastic Small Round Cell Tumor Controlled by an Anthracycline-Based Regimen: Review of the Role of Chemotherapy.Mrabti H, Kaikani W, Ahbeddou N, Abahssain H, El Khannoussi B, Amrani M, Errihani H. J Gastrointest Cancer 2012, 43:103-109

7. Growing teratoma syndrome and peritoneal gliomatosis. Mrabti H, El Ghissassi I, Sbitti Y, Amrani M, Hachi H, Errihani H. Case Report Med. 2011;2011: 123527. Epub 2011 Apr 7.

8. Mrabti H, Chelghoum M, Odier L, Chassagne-Clément C, Pavic M, Devaux Y. Pleural extramedullary hematopoiesis. Rev Med Interne 2008; 29: 573–576

 9. Chemonaïveté in inoperable malignant bowel obstruction. Boutayeb S, Ghissassi IE, Mrabti H, Errihani H. Curr Oncol. 2017 Feb;24(1):e75.

10. Errihani H, M'rabti H, Ismaili N, Inrhaoun H, Elghissassi I. Phase II trial of capecitabine and cisplatin in advanced, persistent, or recurrent carcinoma of the cervix. Int J Gynecol Cancer. 2011 Feb;21(2):373-7.

11. Errihani H, Mrabti H, Sbitti Y, Kaikani W, El Ghissassi I, Afqir S, Boutayeb S, Farik M, Riadi A, Hammoudi M, Chergui H. Psycho-social and religious impact of cancer diagnosis on Moroccan patients: experience from the National Oncology Center of Rabat. Bull Cancer. 2010 Apr;97(4):461-8.

12. Errihani H, Mrabti H, Boutayeb S, El Ghissassi I, El Mesbahi O, Hammoudi M, Chergui H, Riadi A. Impact of cancer on Moslem patients in Morocco. Psychooncology. 2008 Jan; 17(1):98-100.

13. S.Raissouni, G.Rais, H.Mrabti, H.Mouzount, H.Errihani. Pancreatic Adenocarcinoma in Young Adults in a Moroccan Population. J Gastrointest Cancer. 2012 Jul 4.

14. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. Rais G, Raissouni S, Aitelhaj M, Naciri S, Rais F, Khoyaali S, Abahssain H, Bensouda Y, Khannoussi B, Mrabti H, Errihani H. BMC Womens Health. 2012 Oct 7;12(1):35.

15. Psychosocial impact of cancer on Moroccan adolescent and young adult: experience of National Institute of Oncology of Rabat.Boulaamane L, Essaadi I, Lalya I, M'rabti H, Errihani H. Bull Cancer. 2011 Oct 1;98(9):981-8.

16. Male breast cancer: a report of 127 cases at a Moroccan institution. Bourhafour M, Belbaraka R, Souadka A, M'rabti H, Tijami F, Errihani H. BMC Res Notes. 2011 Jun 29;4:219 17. Primary malignant tumors of the small intestine: clinical and therapeutic aspects of 27 patients. Abahssain H, Mokrim M, Lalya I, M'rabti H, Errihani. H. Pan Afr Med J. 2011;8:18..

18. Breast cancer in moroccan young women: a retrospective study. Abahssain H, Lalya I, El M'rabet FZ, Ismaili N, Razine R, Tazi MA, M'rabti H, El Mesbahi O, Benjaafar N, Abouqal R, Errihani H. BMC Res Notes. 2010 Nov 8;3:286.

19. Treatment of chemotherapy-induced nausea and vomiting.H. Inrhaoun, T.Kullman, I.ELGhissassi, H.M'rabti, H.Errihani. J Gastrointest Cancer 2012 Jun 26.

 20. Proteine tyrosine kinase inhibitors in cancer therapy. Boutayeb S, Zakkouri FZ, Ait ElHaj M, Mesmoudi M, Boutayeb A, Boutayeb W, Mrabti H, H.Errihani. Pathol Biol (Paris). 2012 Aug;60(4):229-33.

21. Gastrointestinal stromal tumors Sekkate S, Kairouani M, Abahssain H, Serji B, Boutayeb S, Mrabti H, Errihani H.. Presse Med. 2012 Oct;41(10):917-26.

22. Chemotherapy in gallbladder carcinoma.Abahssain H, Afchain P, Melas N, Ismaili N, Rahali R, M Rabti H, Errihani H. Presse Med. 2010 Dec;39(12):1238-45. Epub 2010 Nov 11.

23. Treatment for metastatic nasopharyngeal carcinoma.Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H, Boussen H, Errihani H. Eur Ann Otorhinolaryngol Head Neck Dis. 2011 Apr;128(2):79-85.

 24. Reduction in HER-2 protein expression in a breast tumor HER-2 positive after only one injection of Trastuzumab: a case report. Elghissassi I, Inrhaoun H, Vignot S, Mrabti H, Errihani H. Cases J. 2009 Jun 9;2:8099.

25. Clinical prognostic factors in locally advanced nasopharyngeal carcinoma in Moroccan population. Raissouni S, Rais G, Lkhoyaali S, Aitelhaj M, Mouzount H, Mokrim M, Razine R, El Kacemi H, Mrabti H, Benjaafar N, Errihani H. Gulf J Oncolog. 2013 Jul;1(14):35-44.

26. Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients. Aitelhaj M, Lkhouyaali S, Rais G, Mohtaram A, Raissouni S, Ghissassi B, Boutayeb S, Mrabti H, Bensouda Y, Errihani H. BMC Res Notes. 2013 Aug 28; 6:339.

27. Frequency and type of epidermal growth factor receptor mutations in moroccan patients with lung adenocarcinoma. Errihani H, Inrhaoun H, Boukir A, Kettani F, Gamra L, Mestari A, Jabri L, Bensouda Y, Mrabti H, Elghissassi I. J Thorac Oncol. 2013 Sep;8(9):1212-4.

28. Ovarian granulosa cell tumors: a retrospective study of 27 cases and a review of the literature. Sekkate S, Kairouani M, Serji B, Tazi A, Mrabti H, Boutayeb S, Errihani H. World J Surg Oncol. 2013 Jun 18; 11:142.

29. Pronostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review. Boulaamane L, Goncalves A, Boutayeb S, Viens P, M'rabti H, Bertucci F, Errihani H. Support Care Cancer. 2013 Aug;21(8):2359-69.

30. Vismodegib: the proof of concept in Basal cell carcinoma. Berrada N, Lkhoyali S, Mrabti H, Errihani H. Clin Med Insights Oncol. 2014 Jun 2;8:77-80.

31. Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma. Elghissassi I, Inrhaoun H, Boukir A, Kettani F, Gamra L, Mestari A, Jabri L, Bensouda Y, Mrabti H, Errihani H. ISRN Oncol. 2014 Mar 5;2014:192493.

32. Granulosa cell tumors of the ovary. Sekkate S, Kairouani M, Serji B, M'Rabti H, El Ghissassi I, Errihani H. Bull Cancer. 2014 Jan 1;101(1):93-101.

 33. HER2 mutations in Moroccan lung adenocarcinoma patients. I. ELGHISSASSI, S.Boutayeb, , Inrhaoun H, Kettani F, Gamra L, Mestari A, Jabri L, Bensouda Y, M'rabti H, Errihani H. Journal of translational internal medicine. Apr-Jun 2014/vol2/issue 2

34. Smoking, passive smoking and lung cancer cell types among women in Morocco: analysis of epidemiological profiling of 101 cases. Zakkouri FA, Saloua O, Halima A, Rachid R, Hind M, Hassan E. BMC Res Notes. 2015 Oct 3;8(1):530.

35. The burden among family caregivers of elderly cancer patients: prospective study in a Moroccan population.Lkhoyaali S, El Haj MA, El Omrani F, Layachi M, Ismaili N, Mrabti H, Errihani H. BMC Res Notes. 2015 Aug 13;8:347.

36. Management of early breast cancer in older women: from screening to treatment. F. Elomrani, M.Zine, I .Ouziane, H. Mrabti , H. Errihani. Breast cancer :targets and therapy. 2015 Jul 7;7:165-71.

37. Bevacizumab in clinical practice. Majid N, Ghissassi I, Mrabti H, Errihani H.Gulf J Oncolog. 2015 Sep;1(19):33-7.

38. Letter to the editor about the toxicity of docetaxel. Boutayeb S, El Ghissassi I, Naceri S, Berrada N, Mrabti H, Errihani H. Support Care Cancer 2015;23:2861.

39. Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach? Elghissassi I, Boutayeb S, Inrhaoun H, Mrabti H, Errihani H. Curr Oncol. 2016 Apr;23(2):e158-9.

40. Breast Adenoid Cystic Carcinoma: A Rare Case Report and Review of the Literature. El Amarti L, Raiss H, Layachi M, Baldé S, Ettahri H, Elghissassi I, Mrabti H, Errihani H. Gulf J Oncolog. 2017 May;1(24):66-69.

41.Chemonaïveté in inoperable malignant bowel obstruction. Boutayeb S, Ghissassi IE, Mrabti H, Errihani H. Curr Oncol. 2017 Feb;24(1):e75. doi: 10.3747/co.24.3362. Epub 2017 Feb 27. No abstract available.

42.Primary Thyroid Lymphoma: Clinicopathologic Characteristics and Therapeutic Outcomes of Six Cases in Morocco. Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco. Gulf J Oncolog. 2016 Sep;1(22):11-

43.Breast metastasis from recurrent gallbladder adenocarcinoma: a case report with review of the literature. Amarti LE, Faouzi H, Salmi N, Ettahri H, Elghissassi I, Mrabti H, Errihani H. J Gastrointest Oncol. 2016 Aug;7(4):E77-80.

44.Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer. El Amarti L, Elghissassi I, Layachi M, Mrabti H, Errihani H. Gulf J Oncolog. 2016 May;1(21):84-8.

45.Concordance with the World Cancer Research Fund/American Institute for Cancer Research recommendations for cancer prevention and colorectal cancer risk in Morocco: A large, population-based case-control study. El Kinany K, Huybrechts I, Kampman E, Boudouaya HA, Hatime Z, Mint Sidi Deoula M, El Asri A, Benslimane A, Nejjari C, Ibrahimi SA, Mrabti H, Abda N, Alaoui R, Gunter MJ, El Rhazi K. Int J Cancer. 2019 Mar 12.

 46. Ait Ouma A, MRABTI H, Rahou H, Razine  Rachid R, Errihani H. BMC Res Notes. 2019 Jun 21;12(1):351. Quality of life of Moroccan patients on the palliative phase of advanced cancer.